Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

NCT03116698 · View on ClinicalTrials.gov ↗

Study Summary

Once or twice daily 12 week treatment in patients with Actinic Keratosis randomized to treatment in one of four arms.

Conditions Studied

Interventions

  • DRUG Low dose DFD07 once daily
  • DRUG High dose DFD07 once daily
  • DRUG High dose DFD07 twice daily
  • DRUG Placebo twice daily

Study Locations (20)

Florida

  • Investigator Site 16 — Boca Raton
  • Investigator Site 8 — Lake City
  • Investigator Site 7 — Miami
  • Investigator Site 19 — Miami
  • Investigator Site 20 — Miami Lakes
  • Investigator Site 17 — Ormond Beach
  • Investigator Site 6 — West Palm Beach

Texas

  • Investigator Site 10 — Austin
  • Investigator Site 4 — Houston
  • Investigator Site 5 — Plano
  • Investigator Site 11 — San Antonio
  • Investigator Site 2 — San Antonio
  • Investigator Site 12 — San Antonio

California

  • Investigator Site 3 — Cerritos
  • Investigator Site 1 — Fremont
  • Investigator Site 9 — Palm Springs
  • Investigator Site 18 — Santa Ana

New Jersey

  • Investigator Site 13 — Verona

New York

  • Investigator Site 15 — Stony Brook

Pennsylvania

  • Investigator Site 14 — Fort Washington

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2017-02-14
Est. Completion 2018-07-05
Phase Phase 2

Sponsor

Dr. Reddy's Laboratories Limited

14 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03116698

The ClinicalTrials.gov registry entry for NCT03116698 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dr. Reddy's Laboratories Limited, which has 14 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Actinic Keratosis (AK) appearing as the primary indexed condition, and to 4 interventions — of which Low dose DFD07 once daily is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03116698 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Florida, Texas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03116698 about?

NCT03116698 is a clinical study titled "A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period". Once or twice daily 12 week treatment in patients with Actinic Keratosis randomized to treatment in one of four arms.

What is the current status of trial NCT03116698?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2017-02-14. Estimated completion is 2018-07-05.

What conditions does trial NCT03116698 study?

This clinical trial studies the following conditions: Actinic Keratosis (AK). These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03116698?

The interventions under investigation include: Low dose DFD07 once daily (DRUG), High dose DFD07 once daily (DRUG), High dose DFD07 twice daily (DRUG), Placebo twice daily (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03116698?

This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 14 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03116698 being conducted?

This trial has 20 study locations across California, Florida, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial